Drugging the undruggable: a computational chemist's view of KRASG12C.

In recent years, the emergence of targeted covalent inhibitors which bind to the G12C mutant of KRAS have offered a solution to this previously intractable target. Inhibitors of KRASG12C tend to be structurally complex, displaying features such as atropisomerism, chiral centres and a reactive covalent warhead. Such molecules result in lengthy and challenging syntheses, and as a consequence critical decisions need to be made at the design level to maximise the chances of success. Here we take a retrospective look into how computational chemistry can help guide and prioritise medicinal chemistry efforts in the context of a series of conformationally restricted tetracyclic quinolines.

[1]  Doyle J Cassar,et al.  Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature , 2020, Expert opinion on therapeutic patents.

[2]  Narcis Fernandez-Fuentes,et al.  Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment , 2018, Nature Communications.

[3]  Caterina Barillari,et al.  Classification of water molecules in protein binding sites. , 2007, Journal of the American Chemical Society.

[4]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[5]  Richard Lonsdale,et al.  Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity , 2017, J. Chem. Inf. Model..

[6]  Malcolm Anderson,et al.  Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. , 2015, Journal of medicinal chemistry.

[7]  Gregory A Ross,et al.  Water Sites, Networks, And Free Energies with Grand Canonical Monte Carlo. , 2015, Journal of the American Chemical Society.

[8]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[9]  R. Lonsdale,et al.  Structure-based design of targeted covalent inhibitors. , 2018, Chemical Society reviews.

[10]  Gregory A Ross,et al.  Ligand Binding Free Energies with Adaptive Water Networks: Two-Dimensional Grand Canonical Alchemical Perturbations , 2018, Journal of chemical theory and computation.

[11]  Yi Liu,et al.  The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors , 2018, Nature Structural & Molecular Biology.

[12]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[13]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[14]  P. Jänne,et al.  A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors. , 2020 .

[15]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[16]  Paul Labute,et al.  LowModeMD - Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops , 2010, J. Chem. Inf. Model..

[17]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[18]  M. Koegl,et al.  Drugging an undruggable pocket on KRAS , 2019, Proceedings of the National Academy of Sciences.

[19]  Kai Zhu,et al.  Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..

[20]  Jonathan W. Essex,et al.  Strategies to Calculate Water Binding Free Energies in Protein-Ligand Complexes , 2014, J. Chem. Inf. Model..

[21]  Michael S Bodnarchuk,et al.  Utilizing Grand Canonical Monte Carlo Methods in Drug Discovery. , 2019, ACS medicinal chemistry letters.

[22]  J. Desai,et al.  Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. , 2019, Journal of Clinical Oncology.

[23]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[24]  Doyle J Cassar,et al.  Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C. , 2020, Journal of medicinal chemistry.

[25]  N. Chen,et al.  Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.

[26]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[27]  G. Vigers,et al.  Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. , 2020, Journal of medicinal chemistry.

[28]  Shuai Liu,et al.  Is Ring Breaking Feasible in Relative Binding Free Energy Calculations? , 2015, J. Chem. Inf. Model..

[29]  Michael S Bodnarchuk,et al.  Water, water, everywhere… It's time to stop and think. , 2016, Drug discovery today.

[30]  K. Haigis.  KRAS Alleles: The Devil Is in the Detail. , 2017, Trends in cancer.

[31]  Themis Lazaridis,et al.  Inhomogeneous Fluid Approach to Solvation Thermodynamics. 2. Applications to Simple Fluids , 1998 .

[32]  T. Lazaridis.  Inhomogeneous Fluid Approach to Solvation Thermodynamics. 1. Theory , 1998 .